Table 1.
Patient demographics and study characteristics.
| Study | Number followed (initial THA) | Follow-up (mo) | Years (THA) | Location | Age (y) | Gender (male) | Time post injury (mo) | Control | Oxford level of evidence | Grade rating |
|---|---|---|---|---|---|---|---|---|---|---|
| Nicol 2021 [19] | 14 | 60 ± 48 | 2007-2018 | The Ottawa Hospital, Ottawa, Canada | 76 ± 8 | 8 | 22 ± 24 (5-77) | NA | 4 | Low |
| Lucchini 2021 [20] | 68 | 142 ± 19.2 (122–212) | 2000-2008 | Orthopedico Rizzoli, Bologna, Italy | 47.7 ± 11.6 (22-75) | 60 | 143 ± 228 (4–480) | NA | 4 | Low |
| Kumar 2021 [21] | 18 | 28 (12-60) | 2015-2020 | King George's Medical University, Lucknow, India | 44.7 (20-68) | 14 | 30 (3-60). | NA | 4 | Low |
| Kassem 2021 [22] | 45 | 124 (84-180) | NA | Elhadara University Hospital/Elmansoura University Hospital, Egypt | 41.4 (32-61) | 39 | 33 (6-80) | NA | 4 | Very low |
| Gracia 2021 [23] | 39 | 70 (24-132) ORIF 50 Cons 90 | 2004-2014 | Hôspital Pierre-Paul Riquet, Toulouse, France | 54 (20-85); ORIF 59, Cons 49, Control 70 | 30 | 29 (4-115) | NA | 4 | Low |
| Rezaie 2020 [13] | 72 | 35 (12-146) | 2000-2017 | Rothman Orthopaedic Institute, Philadelphia, USA | 57 (25-89) | 37 | 28 ± 32 (1-141) | Primary THA (n=216) | 3 | Low |
| Moon 2020 [24] | 37 | 79 (24-145) | 2002-2017 | Asan Medical Center, Seoul, South Korea | 56.2 (24-81) | 27 | 58 (4–336) | NA | 4 | Low |
| Busch 2020 [25] | 48 (67) | 54 ± 23 (14–88) | 2007-2012 | BG Trauma Center, Tübingen, Germany | 58.5 ± 12.4 (25–87); ORIF 56.2, Cons 63.1 | NA | 107.3 ± 141.9 (1–504) | NA | 4 | Low |
| Garcia Rey 2020 [26] | 78 | 133 (60-276) ORIF 122 Cons 140 | 1986-2012 | Hospital La Paz, Madrid, Spain | 56.9 (23-84); ORIF 52.9, Cons 59.3 | 48 | 69.4 | NA | 4 | Very low |
| Do 2020 [27] | 25 | 50 (24-222) | 2000-2016 | Pusan National University Hospital, Busan, South Korea | 58 (36-85) | 19 | 70 (7-213) | NA | 4 | Very low |
| Dawson 2019 [4] | 25 | 22 | 2013-2017 | Tallaght University Hospital, Dublin Ireland | 53.8 | 17 | 28 | NA | 4 | Very low |
| Taheriazam 2019 [28] | 49 | 44 (24-60) | 1998-2015 | Erfan and Milad Hospital, Tehran, Iran | (17-68) | 43 | 74 (38-205) | NA | 4 | Very low |
| Lee 2019 [29] | 57 | 94 ± 29 | 2003-2012 | Euliji Medical Centre, Seoul, South Korea | 52 ± 13.6 | 31 | 228 (2-720) | Primary THA (n=57) | 3 | Low |
| Wang 2018 [30] | 33 | 138 ± 36 (96-204) | 1997-2008 | Affiliated Hospital of Jiangnan University, Jiangsu, China | 45.1 ± 9.3 (25–68) | 21 | 58 (4-240) | NA | 4 | Low |
| Salama 2017 [31] | 21 | 26 (24–36) | 2011-2014 | San Luigi Hospital of Orbassano, Turin Italy | 57 (29–75) | 12 | NA | NA | 4 | Very low |
| Clarke-Jensson 2017 [32] | 52 | Median 88 (12-252) | 1995-2004 | Multicentre, 6 Norwegian Hospitals | Median 54 (11-82) | 35 | 48 (1-169) | NA | 4 | Low |
| Gavaskar 2017 [33] | 44 (47) | ORIF 82 ± 117 Cons 85 ± 16 | 2006–2010 | Parvathy Hospital, Chennai, India | 47.9 | 31 | 29.2 | NA | 4 | Very low |
| Morison 2016 [34] | 74 | 120 (24-288) | 1987-2011 | St Michaels Hospital, Toronto, Canada | 51 (25–75) | 50 | 48 (12-288) | Primary THA (n=74) | 3 | Low |
| Yuan 2015 [35] | 28 (30) | 60 (25-120) | 1999-2010 | Mayo Clinic, Rochester, USA | 45 (23-75) | 21 | 107 (4-504) | NA | 4 | Low |
| Chiu 2015 [36] | 56 | 120 (60-180) | 1996-2010 | Taipei Veterans Hospital, Taipei, Taiwan | 54.1 (19-86) | 39 | 27 (6-114) | NA | 4 | Low |
| Schnaser 2014 [37] | 17 | 77 ± 33 | 2000-2011 | Metrohealth Medical Centre, Cleveland, USA | 69 (60–81) | 13 | 35 (9-144) | Primary THA (n=44) | 3 | Very low |
| Lizaur Utrilla 2012 [38] | 24 | 101 (60-180) | 1992-2005 | Hospital General Elda, Alicante, Spain | 56.4 (28-77) | 19 | 36 (5-168) | Primary THA (n=48) | 3 | Low |
| Lai 2011 [39] | 31 | 76 (37–101) | 2000-2003 | West China Hospital, Chengdu, China | 51 (27-74); ORIF 50, Cons 52 | 22 | 67 (9-210) | NA | 4 | Low |
| Zhang 2011 [40] | 51 (55) | 64 (32-123) | 1998-2007 | Jishuitan Hospital, Beijing, China | 46.6 (22-65) | 42 | 79.2 (7-360) | NA | 4 | Very low |
| Ranawat 2009 [12] | 32 | 59 (48-116) | 1995-2003 | Hospital for Special Surgery, New York, USA | 52 (20-87) | 23 | 36 (1-227), | NA | 4 | Low |
| Bellabarba 2001 [41] | 30 | 63 (24-140) | 1984-1995 | Rush-Presbyterian-St Luke’s,, Chicago, USA | 51 (26-86); ORIF 50, Cons 52 | 14 | 37 (8-444) | Primary THA (n=204) | 3 | Very low |
| Sarkar 2001 [42] | 22 (37) | 48 (15-168) | 1982-2000 | University of Ulm, Germany | 44 (20-74) | NA | 37 (4-235) | NA | 4 | Very low |
| Huo 1999 [43] | 21 | 65 (48-104) | 1985-1993 | Keggi Orthopaedic Foundation, Connecticut, USA | 52 (23-78) | 19 | 164 (8-480) | NA | 4 | Low |
| Weber 1998 [44] | 63 (66) | 115 (24–240) | 1970-1993 | Mayo Clinic, Rochester, USA | 52 (19-80) | NA | 108 | NA | 4 | Very low |
ORIF, open reduction internal fixation group; Cons, conservative (nonoperative) group.